

June 1, 2022 Web Announcement 2793

## Emergency Use Authorization Revoked for Monoclonal Antibody Injection Code Q0247 and Infusion Codes M0247 and M0248

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) revocation for the monoclonal antibody procedure codes listed below due to the high frequency of the Omicron variant. The following injection and infusion/administration codes are not authorized effective with dates of service on or after April 5, 2022, and may not be administered for treatment or post-exposure prevention of COVID-19 under the EUA until further notice by the FDA.

| Procedure Code | Description   |
|----------------|---|
| Q0247          | GSK, Sotrovimab, Injection, 500mg   |
| M0247          | GSK, Sotrovimab, Infusion, includes intravenous infusion and post administration monitoring                             |
| M0248          | GSK, Sotrovimab, Infusion, home admin, intravenous infusion and post administration monitoring in the home or residence |

The following provider types (PTs) are impacted:

| Provider Type | Description                               |
|---------------|---|
| 12            | Hospital, Outpatient                      |
| 20            | Physician, M.D., Osteopath, D.O.          |
| 24            | Advanced Practice Registered Nurse (APRN) |
| 77            | Physician's Assistant                     |

**Providers are encouraged to cease billing the above procedure codes in order to avoid recoupment of paid claims.** Claims for the above codes with dates of service on or after April 5, 2022, that are paying instead of denying with error code 3340 (Service not covered by Nevada Medicaid) may be reprocessed automatically to recoup the payments. A future web announcement will notify providers if claims are reprocessed.

When claims are reprocessed, please be aware that all system and clinical claim editor edits are applicable. As a result, there may be no additional payment, and other claim denials may be received. Providers have the right to appeal denied claims, including those denied upon reprocessing. Please refer to <u>Medicaid Services Manual Chapter</u> <u>100</u> and the <u>Billing Manual</u> for information concerning the claim appeal process and time frames.

For additional COVID-19 information, please see the Division of Health Care Financing and Policy (DHCFP) COVID-19 webpage at: <u>https://dhcfp.nv.gov/covid19/</u>. A Member Outreach page is now available with resources related to COVID-19 that providers and partners can distribute to members. The page is available at: <u>https://dhcfp.nv.gov/Pgms/CPT/COVID-19/MemberOutreach/</u>